Related references
Note: Only part of the references are listed.2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETES CARE (2020)
Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis
Jessica A. Huthmacher et al.
DIABETES CARE (2020)
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Carolyn F. Deacon
NATURE REVIEWS ENDOCRINOLOGY (2020)
Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes
Athena Philis-Tsimikas et al.
DIABETES OBESITY & METABOLISM (2019)
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
Bernard Zinman et al.
DIABETES CARE (2019)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study
Ronan Roussel et al.
DIABETES OBESITY & METABOLISM (2019)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine
Chantal Mathieu et al.
DIABETES THERAPY (2015)
A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine
Chantal Mathieu et al.
DIABETES THERAPY (2015)
Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus
Muhammad A. Abdul-Ghani et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3,26 week, randomised, open-label, treat-to-target, non-inferiority trials
Bernard Zinman et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients
K. Esposito et al.
DIABETES OBESITY & METABOLISM (2012)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs
Sanne G. Swinnen et al.
DIABETES CARE (2010)
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
T. Vilsboll et al.
DIABETES OBESITY & METABOLISM (2010)
A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes
L. Fogelfeld et al.
DIABETIC MEDICINE (2010)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
J. Rosenstock et al.
DIABETOLOGIA (2008)
Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus
V. Fonseca et al.
HORMONE AND METABOLIC RESEARCH (2008)
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
V. Fonseca et al.
DIABETOLOGIA (2007)
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes
Kjeld Hermansen et al.
DIABETES CARE (2006)
Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: An assessment of treatment flexibility
E. Standl et al.
HORMONE AND METABOLIC RESEARCH (2006)
Insulin secretion and insulin sensitivity at different stages of glucose tolerance: A cross-sectional study of Japanese type 2 diabetes
M Fukushima et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2004)
Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes -: A randomized, controlled trial
A Fritsche et al.
ANNALS OF INTERNAL MEDICINE (2003)
The treat-to-target trial - Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
MC Riddle et al.
DIABETES CARE (2003)
Share Paper
